幽门螺杆菌β-内酰胺耐药分子机制及其对多重耐药的贡献
本文综述幽门螺杆菌对β-内酰胺类抗生素耐药的分子机制,包括青霉素结合蛋白突变、β-内酰胺酶产生、外膜通透性改变和外排泵激活,这些机制降低β-内酰胺疗效并促进多重耐药菌株出现,理解这些通路对开发新治疗策略至关重要。
要点
- 幽门螺杆菌β-内酰胺耐药涉及PBPs突变、β-内酰胺酶、外膜通透性改变和外排泵四类机制。
- 上述机制不仅削弱β-内酰胺杀菌效果,还推动多重耐药幽门螺杆菌菌株产生。
- 阐明耐药分子通路是开发克服耐药新策略、提升根除疗效的关键基础。
核心结论
- 幽门螺杆菌β-内酰胺耐药由多种分子机制共同介导,并促进多重耐药菌株出现。
研究设计与样本
- 本文为综述,围绕幽门螺杆菌β-内酰胺耐药及多重耐药的分子机制进行汇总。
主要发现
- β-内酰胺耐药机制包括青霉素结合蛋白突变、β-内酰胺酶产生、外膜通透性改变和外排泵激活。
- 这些机制降低β-内酰胺抗生素疗效,并促成多重耐药幽门螺杆菌菌株的出现。
临床怎么用
- 理解β-内酰胺耐药分子通路有助于开发新型治疗策略以克服耐药并提高幽门螺杆菌感染疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Helicobacter pylori is a significant pathogen associated with a range of diseases, most notably gastritis and gastric cancer, making it a critical target for medical intervention. β-lactam antibiotics, known for their potent bactericidal properties, play a central role in clinical regimens aimed at eradicating H pylori. However, the increasing resistance of H pylori to β-lactams, compounded by the rise of multidrug-resistant strains, presents a major challenge to effective treatment. The molecular mechanisms underlying β-lactam resistance in H pylori are multifactorial, including (1) mutations in penicillin-binding proteins, (2) production of β-lactamases, (3) alterations in outer membrane permeability, and (4) activation of efflux pumps. These mechanisms not only reduce the efficacy of β-lactam antibiotics but also contribute to the emergence of multidrug-resistant H pylori strains. Understanding these molecular pathways is essential for the development of novel therapeutic strategies to overcome resistance and enhance the effectiveness of treatment for H pylori infections.
引用
- Zhou J, Tang X, He L, et al. Molecular Mechanisms of β-Lactam Resistance and Its Contribution to Multidrug Resistance in Helicobacter pylori. J Infect Dis. 2026. PMID: 41824654. doi:10.1093/infdis/jiaf385
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。